Table 2. Association of variant alleles in BRCA1, NBS1 and CHEK2 with prostate cancer risk, by age.
| Controls (n=3956) No. (%) | Cases diagnosed at age ⩽60 years (n=619) No. (%) | OR | 95% CI | P-value | Cases diagnosed at age >60 years (n=3131) No. (%) | OR | 95% CI | P-value | |
|---|---|---|---|---|---|---|---|---|---|
| Any BRCA1 mutation | 17 (0.4%) | 5 (0.8%) | 1.9 | 0.7–5.1 | 0.9 | 9 (0.3%) | 0.7 | 0.3–1.5 | 0.6 |
| 5382insC | 13 (0.3%) | 1 (0.2%) | 0.5 | 0.1–3.8 | 0.8 | 5 (0.2%) | 0.5 | 0.2–1.4 | 0.2 |
| C61G | 3 (0.08%) | 1 (0.2%) | 2.1 | 0.2–20.5 | 1.0 | 2 (0.06%) | 0.8 | 0.1–5.0 | 0.8 |
| 4153delA | 1 (0.03%) | 3 (0.5%) | 20.3 | 2.0–185.6 | 0.004 | 2 (0.06%) | 2.5 | 0.2–27.9 | 0.8 |
| |
|
|
|
|
|
|
|
|
|
| NBS1 mutation | |||||||||
| 657del5 | 23 (0.6%) | 11 (1.8%) | 3.1 | 1.5–6.4 | 0.003 | 43 (1.4%) | 2.4 | 1.4–4.0 | 0.0009 |
| |
|
|
|
|
|
|
|
|
|
| Any CHEK2 mutation | 228 (5.8%) | 77 (12.4%) | 2.3 | 1.8–3.1 | <0.0001 | 306 (9.8%) | 1.8 | 1.5–2.1 | <0.0001 |
| |
|
|
|
|
|
|
|
|
|
| Any CHEK2 truncating mutation | 43 (1.1%) | 16 (2.6%) | 2.4 | 1.4–4.3 | 0.004 | 68 (2.2%) | 2.0 | 1.4–3.0 | 0.0004 |
| 1100delC | 7 (0.2%) | 4 (0.6%) | 3.7 | 1.1–12.6 | 0.08 | 17 (0.5%) | 3.1 | 1.2–7.4 | 0.02 |
| IVS2+1G>A | 21 (0.5%) | 4 (0.6%) | 1.2 | 0.4–3.6 | 0.9 | 24 (0.8%) | 1.4 | 0.8–2.6 | 0.3 |
| del5395 | 15 (0.4%) | 8 (1.3%) | 3.4 | 1.5–8.2 | 0.007 | 27 (0.9%) | 2.3 | 1.2–4.3 | 0.01 |
| |
|
|
|
|
|
|
|
|
|
| CHEK2 I157T missense mutation | 186 (4.7%) | 62 (10.0%) | 2.3 | 1.7–3.0 | <0.0001 | 241 (7.7%) | 1.7 | 1.4–2.1 | <0.0001 |
Abbreviations: CI=confidence interval; HR=hazard ratio.
ORs and P-values are calculated with respect to controls as reference group.